Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide +/- ATRA for Resistant Hematologic Malignancy
NCT00006220Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jun 1999
- Primary completion
- Nov 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 6 months. Started Jun 1999; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00006220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006220.